Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ITRM vs JNJ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JNJ Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

JNJ Overall Winner 6-Pillar Tally: ITRM 0 – 6 JNJ Matrix Metrics: ITRM 0 – 10 JNJ

As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin).

  • Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile JNJ trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ITRM vs JNJ
ITRM NASDAQ
Iterum Therapeutics plc Ordinary Share
Pharmaceutical Preparations
$0.03
-57.39% 1D
Market Cap $3.8M
TTM Revenue $390,000
Forward P/E N/M
Beta / 30D Vol 1.61β · 508% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 75.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.9%), weak momentum, RSI 26
RSI-14: 25.9 · SMA20: $0.15 · SMA50: $0.23
JNJ NYSE Head-to-Head Winner
Johnson & Johnson
Pharmaceutical Preparations
$270.47
+1.25% 1D
Market Cap $643.1B
TTM Revenue $99.3B
Forward P/E 23.3x
Beta / 30D Vol -0.04β · 25% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 47.0 Fund 54.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $275.01 · SMA50: $267.43

6-Pillar Scorecard Institutional Category Breakdown (ITRM 0 – 6 JNJ)

Columns: Metric · ITRM · JNJ
1. Valuation Multiples JNJ
Forward P/E N/M 23.3x
Trailing P/E N/M 40.5x
PEG Ratio N/M 3.07x
EV / Revenue 9.6x 6.8x
2. Growth & Scale JNJ
Revenue Growth (YoY) -100.0% +5.9%
Earnings Growth (YoY) +0.0% -95.9%
TTM Revenue (USD) $390,000 $99.3B
Market Cap $3.8M $643.1B
3. Profitability & Quality JNJ
Gross Margin 29.7% 67.8%
Operating Margin -1982.3% 26.6%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -555.7% 20.0%
4. Balance Sheet & Cash Flow JNJ
Cash Generation (TTM) -$19M EBITDA $19.6B
Cash Flow Margin N/A 19.7%
Net Cash / Leverage -555.7% ROE $27.7B Net Debt (0.55x D/E)
Dividend Yield None (0.00%) 1.94%
5. Options & Positioning JNJ
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 34.7% (45th %ile)
Put/Call OI Skew N/A 0.76x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat JNJ
OpEx & R&D Intensity N/A 41.2% of Rev ($40.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ITRM (0) vs JNJ (10)
Institutional Metric ITRM JNJ Criterion Row Edge
Market Capitalization
Scale
$3.8M $643.1B Larger Scale JNJ
Trailing P/E Ratio
Valuation
N/M 40.5x Lower Multiple JNJ
Forward P/E Ratio
Valuation
N/M 23.3x Lower Multiple JNJ
Revenue Growth (YoY)
Growth
-100.0% +5.9% Higher Growth JNJ
Operating Margin (TTM)
Profitability
-1982.3% 26.6% Higher Margin JNJ
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin JNJ
Return on Equity (ROE)
Capital Efficiency
-555.7% 20.0% Higher ROE JNJ
52-Week Range Position
Momentum
0% ($0–$1) 78% ($199–$290) Stronger Trend JNJ
Beta / 30D Volatility
Risk Regime
1.61β · 508% Vol -0.04β · 25% Vol Lower Realized Risk JNJ
Unified Institutional Score
Composite Signal
50.5 / 100 (HOLD) 57.8 / 100 (HOLD) Higher Composite JNJ
Trailing 12M Revenue (USD)
Operating Scale
$390,000 $99.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.7% 67.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev 3.07x PEG · 6.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M EBITDA (-555.7% ROE) $19.6B ($27.7B Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JNJ +87.72 pp
ITRM: -89.38% · JNJ: -1.66%
3M Horizon JNJ +107.39 pp
ITRM: -89.62% · JNJ: +17.77%
6M Horizon JNJ +112.92 pp
ITRM: -92.21% · JNJ: +20.71%
1Y Horizon JNJ +112.92 pp
ITRM: -92.21% · JNJ: +20.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITRM vs JNJ. Trailing 12-month operating profitability (ITRM -1982.3% vs JNJ 26.6%) and valuation multiples (ITRM N/M vs JNJ 23.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ITRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$390,000
Gross Margin29.7%
Op. Margin-1982.3%
ROE / Fwd P/E-555.7% · N/M
JNJ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$99.3B
Gross Margin67.8%
Op. Margin26.6%
ROE / Fwd P/E20.0% · 23.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ITRM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JNJ CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 34.7%
IV Percentile 45th %ile
Put/Call OI Skew 0.76x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact JNJ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $282.55 · IV 26.6%

JNJ Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($28,255)

Compare $28,255 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 26.6% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $280 / $300 Bull Call Spread

Buy 1x $280C · Sell 1x $300C · 31d

Net Entry $742 Debit
T+5d @ +5% Move +$526 (+71%)
Max Risk / Buffer $742 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $270 / $260 Bull Put Spread

Sell 1x $270P · Buy 1x $260P · 31d

Net Entry $240 Credit
Max Credit / Yield +$240 (+31.6% RoM)
Max Risk / Buffer -5.3% Cushion ($760 Mgn)
5d Edge & Liquidity 73% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 11 $265P / $285-$295C Seagull

Sell 1x $265P · Buy 1x $285/$295C · 24d

Net Entry $136 Debit
T+5d @ +5% Move +$486 (+11.4% RoM)
Max Risk / Buffer -6.2% Put Cushion ($4,261 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ITRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8M market capitalization and -1982.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
JNJ Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $643.1B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($40.9B)
90D Engineering Disclosures 0 Published

Investor FAQ ITRM vs JNJ Key Questions & Quantitative Answers

As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Iterum Therapeutics plc Ordinary Share (ITRM) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ITRM carries a Unified Composite Score of 50.5/100 (HOLD) at $0.03 (N/M Forward P/E, -1982.3% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin). Technical & Structure Timing Caution: ITRM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.9); meanwhile JNJ trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

JNJ leads the Growth & Scale pillar: ITRM posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $390,000 TTM revenue (29.7% gross margin, -1982.3% operating margin), compared with JNJ at +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin). On trailing 12-month operating scale, ITRM generates $390,000 in USD-normalized revenue versus $99.3B for JNJ. In operating R&D and SG&A reinvestment, ITRM deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($40.9B) (0 disclosures) for JNJ.

JNJ screens cheaper on headline valuation multiples. ITRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas JNJ trades at 23.3x Forward P/E, 40.5x Trailing P/E, 3.07x PEG, and 6.8x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITRM (-555.7% ROE) versus JNJ (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ITRM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 508% Vol realized risk). By comparison, JNJ carries 34.7% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.